Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results
Authors
Keywords
-
Journal
EYE
Volume 29, Issue 3, Pages 342-349
Publisher
Springer Nature
Online
2014-10-31
DOI
10.1038/eye.2014.258
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
- (2014) Irmela Mantel et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research
- (2014) Armin Wolf et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Ranibizumab Treatment in Age-Related Macular Degeneration: A Meta-Analysis of One-Year Results
- (2014) H. Gerding KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
- The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections
- (2014) OPHTHALMOLOGY
- Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark
- (2013) Patrizia Tschuor et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Current Anti–Vascular Endothelial Growth Factor Dosing Regimens
- (2013) Julia A. Haller OPHTHALMOLOGY
- Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
- (2013) Brandon G. Busbee et al. OPHTHALMOLOGY
- Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
- (2013) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- Age-Related Macular Degeneration, Anti-VEGF Therapy, and Ophthalmic Imaging
- (2013) Dennis P. Han JAMA Ophthalmology
- Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
- (2012) Sara Brandi Bloch et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration
- (2012) Irmela Mantel et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
- (2012) Usha Chakravarthy et al. OPHTHALMOLOGY
- Myositis Ossificans
- (2011) Deborah A. Martin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
- (2011) Frank G. Holz et al. OPHTHALMOLOGY
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2
- (2010) Prema Abraham et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Behandlung der feuchten altersabhängigen Makuladegeneration mit weniger als 12 Ranibizumab-Injektionen pro Jahr
- (2010) H. Gerding KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
- A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationClinical and Economic Impact
- (2010) Omesh P. Gupta et al. OPHTHALMOLOGY
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
- (2010) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical Trials
- (2010) Philip J. Rosenfeld et al. OPHTHALMOLOGY
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
- (2009) Geeta A. Lalwani et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration
- (2009) Hajir Dadgostar et al. OPHTHALMOLOGY
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
- (2008) Carl D. Regillo et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
- (2008) David M. Brown et al. OPHTHALMOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More